Tryptamine compositions for enhancing neurite outgrowth
Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum ) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis , optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
1. A method of treating or reducing symptoms of a mood disorder in a subject in need thereof, the method comprising:
administering to the subject a pharmaceutical dosage form comprising:
1 mg to 10 mg of psilocybin or psilocin; and
one or more pharmaceutically acceptable excipients,
1 to 6 times per day sufficient to treat or reduce the symptoms of the mood disorder in the subject.
2. The method of claim 1 , wherein the pharmaceutical dosage form comprises 1 mg, 2 mg, 3 mg, 4 mg, 5, mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg of psilocybin or psilocin.
3. The method of claim 1 , wherein the pharmaceutical dosage form comprises psilocybin containing mushrooms or extracts thereof.
4. The method of claim 1 , wherein the pharmaceutical dosage form further comprises 10 μg to 200 mg of one or more adversives.
5. The method of claim 4 , wherein the one or more adversives comprises niacin, ipecac, apomorphine, bittering agents, denatonium benzoate, capsaicin, capsacutin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, capsaicinoids, gingerol, pipeline, isopiperine, zingerone, shogaol, vanillylamide derivatives, or combinations thereof.
6. The method of claim 4 , wherein the one or more adversives comprises niacin.
7. The method of claim 1 , wherein the pharmaceutical dosage form is a capsule comprising a powder admixture, liquid, suspension, or emulsion.
8. The method of claim 1 , wherein the pharmaceutically acceptable excipients comprise one or more fillers, binders, diluents, vehicles, lubricants, preservatives, flavors, colorants, or combinations thereof.
9. The method of claim 1 , wherein the mood disorder comprises depression, anxiety, major depressive disorder, treatment resistant depression, persistent depression, manic depression or bipolar disorder, depressive psychosis, perinatal depression, premenstrual dysphoric disorder, seasonal depression, situational depression, panic disorder, post-traumatic stress disorder, obsessive compulsive disorder, or substance abuse disorders.
10. A method of treating or reducing symptoms of depression or anxiety in a subject in need thereof, the method comprising:
administering to the subject a pharmaceutical dosage form comprising:
1 mg to 10 mg of psilocybin or psilocin; and
one or more pharmaceutically acceptable excipients,
1 to 6 times per day sufficient to treat or reduce the symptoms of depression or anxiety in the subject.
11. The method of claim 10 , wherein the pharmaceutical dosage form comprises 1 mg, 2 mg, 3 mg, 4 mg, 5, mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg of psilocybin or psilocin.
12. The method of claim 10 , wherein the pharmaceutical dosage form comprises psilocybin containing mushrooms or extracts thereof.
13. The method of claim 10 , wherein the pharmaceutical dosage form further comprises 10 μg to 200 mg of one or more adversives.
14. The method of claim 13 , wherein the one or more adversives comprises niacin, ipecac, apomorphine, bittering agents, denatonium benzoate, capsaicin, capsacutin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, capsaicinoids, gingerol, pipeline, isopiperine, zingerone, shogaol, vanillylamide derivatives, or combinations thereof.
15. The method of claim 13 , wherein the one or more adversives comprises niacin.
16. The method of claim 10 , wherein the pharmaceutical dosage form is a capsule comprising a powder admixture, liquid, suspension, or emulsion.
17. The method of claim 10 , wherein the pharmaceutically acceptable excipients comprise one or more fillers, binders, diluents, vehicles, lubricants, preservatives, flavors, colorants, or combinations thereof.
18. The method of claim 10 , wherein the depression comprises major depressive disorder, treatment resistant depression, persistent depression, manic depression or bipolar disorder, depressive psychosis, perinatal depression, premenstrual dysphoric disorder, seasonal depression, or situational depression.